文献速递自身炎症与 IgG4 相关病

儿童及青少年家族性地中海热:秋水仙碱剂量影响因素与剂量增加预测参数

Familial Mediterranean fever in children and adolescents: factors for colchicine dosage and predicting parameters for dose increase.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

基于409例儿童家族性地中海热(FMF)患者、4566次就诊的国家自身炎症性疾病登记数据,分析影响秋水仙碱个体剂量的因素。研究发现基因型影响年龄相关剂量,体表面积与应用剂量相关性最佳;秋水仙碱引入和剂量增加可显著减少临床症状和炎症;单个生物标志物升高使未来12个月剂量增加风险增加1.62–1.94倍,联合S100分子可提高至4.66倍(高危患者7.27倍)。

要点

  • 基因型影响儿童FMF患者年龄相关的秋水仙碱剂量,体表面积是与剂量相关性最佳的人体测量参数
  • 秋水仙碱引入及剂量增加可显著减少临床症状和炎症
  • 单个生物标志物升高使未来12个月剂量增加风险增加1.62–1.94倍,联合S100分子可提高至4.66倍(高危患者7.27倍)

核心结论

  • 秋水仙碱治疗目前主要由临床症状和血清学炎症指导,基因型、体表面积和生物标志物有助于更个体化管理。
  • 额外分析S100分子作为敏感生物标志物有助于识别近期需要增加剂量的患者。

研究设计与样本

  • 分析来自国家自身炎症性疾病登记处的409例儿童FMF患者(4566次就诊)数据。
  • 通过ELISA测定血清S100分子浓度。

主要发现

  • 年龄相关秋水仙碱剂量受现基因型影响。
  • 体表面积是与应用剂量相关性最佳的人体测量参数。
  • 秋水仙碱引入和剂量增加导致临床症状和炎症显著减少。
  • 在已建立的秋水仙碱治疗期间,单个生物标志物升高使未来12个月剂量增加的可能性增加1.62–1.94倍。
  • 包含S100分子的生物标志物组合使该比值比在所有患者中提高至4.66,在重症高危患者中提高至7.27。

关键数值与推荐

  • 单个生物标志物升高使未来12个月剂量增加的风险增加1.62–1.94倍。
  • 包含S100分子的生物标志物组合使比值比在所有患者中提高至4.66,在重症高危患者中提高至7.27。

临床怎么用

  • 儿童FMF秋水仙碱剂量调整可结合基因型、体表面积及生物标志物进行个体化管理。
  • 监测生物标志物(尤其S100分子)有助于识别未来12个月内可能需要增加剂量的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim was to analyse factors influencing the individual colchicine dose in children with FMF, to evaluate the impact of dose adjustment on the clinical course and inflammation and to identify clinical parameters and biomarkers that predict dose increase in the near future. METHODS: Data from 409 paediatric FMF patients (4566 visits) derived from the national auto-inflammatory diseases registry were analysed. Serum concentrations of S100 molecules were determined by ELISA. RESULTS: The age-dependent colchicine dose is influenced by the present genotype. The body surface area is the anthropometric parameter that correlates best with the applied dosages. Colchicine introduction and dose increase lead to significant reduction of clinical symptoms and inflammation. During established colchicine therapy, an increase of one single biomarker increases the likelihood of a dose increment in the next 12 months with a factor of 1.62-1.94. A combination of biomarkers including S100 molecules increases this odds ratio up to 4.66 when analysing all patients and up to 7.27 when analysing patients with a high risk of severe disease. CONCLUSION: Colchicine therapy is currently guided mainly by the occurrence of clinical symptoms and serological inflammation. Other factors, such as the genotype, the body surface area and biomarkers, will help to manage colchicine therapy in a more individualized fashion. The additional analysis of S100 molecules as sensitive biomarkers will help to identify patients at risk for dose increases in the near future.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Knieper AM, Klotsche J, Lainka E, et al. Familial Mediterranean fever in children and adolescents: factors for colchicine dosage and predicting parameters for dose increase. Rheumatology (Oxford). 2017. PMID: 28859329. doi:10.1093/rheumatology/kex222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。